This guide is designed for aerosol production managers, R&D professionals, and procurement specialists. It provides a systematic overview of pharmaceutical aerosol propellant types, selection criteria, filling process compatibility, and regulatory compliance, helping you make informed decisions at every stage of product development and equipment sourcing.
1. Propellants: The Powerhouse of Pharmaceutical Aerosols
Propellants are a core component of pharmaceutical aerosols, providing the driving force that delivers the drug in a metered, stable, and atomized spray. In terms of working principle, propellants typically have boiling points below room temperature at atmospheric pressure and maintain high vapor pressure inside the sealed container. When the valve is actuated, the internal pressure is suddenly released to atmospheric pressure, causing the propellant to vaporize rapidly and expand, ejecting the liquid drug as a fine mist. In some formulations, the propellant also acts as a solvent or diluent, directly influencing droplet size, spray pattern, and drug deposition.
The choice of propellant not only affects product performance but also directly impacts patient safety and therapeutic efficacy. An ideal pharmaceutical propellant should meet the following criteria:
l Pressure characteristics: Vapor pressure above atmospheric pressure at room temperature
l Safety profile: Non-toxic, non‑allergenic, non‑irritating
l Stability: Inert — no reaction with drug substances or container materials
l Physical properties: Colorless, odorless, tasteless
l Safety: Non‑flammable, non‑explosive
l Economics: Affordable and readily available
As environmental regulations have tightened globally, propellant selection has evolved from a purely performance-driven decision to a complex trade-off involving efficacy, safety, environmental impact, and regulatory compliance.
2. The Four Main Types of Propellants
Based on chemical structure and working principle, pharmaceutical aerosol propellants fall into four categories. Understanding the characteristics, advantages, and limitations of each type is essential for formulation development and equipment selection.
2.1 Hydrofluoroalkanes (HFAs) — The Mainstream Choice
Hydrofluoroalkanes are currently the most promising class of propellants and the mainstream replacement for chlorofluorocarbons (CFCs). HFAs offer zero ozone depletion potential, low toxicity, and high stability. They are widely used in asthma and COPD therapies, especially in pressurized metered‑dose inhalers (pMDIs).
The two most common HFA propellants in pharmaceutical aerosols are:
(1) HFA‑134a (Tetrafluoroethane)
HFA‑134a is the most widely used HFA propellant, with a boiling point of ‑26.3°C and moderate vapor pressure. It is chemically stable and provides consistent pressure output at room temperature, allowing the drug to be emitted as a uniform, fine mist. Most existing HFA‑based inhalation aerosols use HFA‑134a as the propellant.
(2) HFA‑227ea (Heptafluoropropane)
HFA‑227ea has a boiling point of ‑17.3°C, slightly higher than HFA‑134a, with correspondingly lower vapor pressure. This makes it advantageous in formulations that require a milder spray force. Industry experts anticipate significant growth in the use of HFA‑227ea in pharmaceutical aerosols in the future.
In practice, HFA propellants can be combined with co‑solvents such as ethanol to improve drug solubility. Corticosteroid pMDI formulations, for example, often contain approximately 13% ethanol to enhance drug solubility. Blending two or more HFA propellants allows manufacturers to fine‑tune vapor pressure and atomization characteristics.
2.2 Compressed Gases — The Safety-First Option
Compressed gas propellants include nitrogen (N₂), carbon dioxide (CO₂), and nitrous oxide (NO). These propellants work by simple physical pressurization — the gas is stored under high pressure, and actuation releases that pressure to expel the drug.
The primary advantages of compressed gases are their chemical stability, non flammability, and low toxicity. Nitrogen is extremely stable, non reactive with drugs, and insoluble in water. Carbon dioxide is also stable but has notable water solubility, which may cause pressure fluctuations over time.
However, compressed gases have significant limitations. When non liquefied compressed gases are filled at room temperature, the internal pressure drops progressively with use, leading to inconsistent spray performance. Additionally, compressed gases produce relatively coarse droplets, making them unsuitable for inhalation products requiring deep lung deposition. Consequently, compressed gases are more commonly found in topical aerosols, space disinfection products, and applications where fine atomization is not critical.
2.3 Hydrocarbons — The Economical Choice
Hydrocarbon propellants include propane, n butane, and isobutane. Their main advantages are low cost, low toxicity, and density close to that of water.
The major drawback of hydrocarbons is their flammability and explosiveness, requiring extremely stringent safety management during production and storage. For this reason, hydrocarbons are rarely used alone in pharmaceutical aerosols; they are typically blended with CFCs to reduce flammability risk. Today, hydrocarbons are more commonly found in consumer aerosol products such as hairsprays and air fresheners, with limited applications in pharmaceutical aerosols.
2.4 Chlorofluorocarbons (CFCs) — Obsolete
Chlorofluorocarbons, commonly known as Freon, include trichlorofluoromethane (CFC 11), dichlorodifluoromethane (CFC 12), and dichlorotetrafluoroethane (CFC 114). Throughout the 20th century, CFCs were the most widely used propellants in pharmaceutical aerosols, prized for their chemical inertness, low toxicity, and stable pressure characteristics.
However, CFCs were found to deplete the Earth‘s ozone layer. Under the Montreal Protocol on Substances that Deplete the Ozone Layer, signatory nations agreed to phase out CFC production globally. China halted CFC use in topical aerosols effective July 1, 2007, and in inhalation aerosols effective January 1, 2010. After July 1, 2013, the production of non inhalation pharmaceutical aerosols using CFCs was also prohibited. CFC propellants are now a matter of history in pharmaceutical aerosols.
3. How Propellants Influence Filling Technology — An OEM‘s Perspective
The choice of propellant directly shapes the filling process design. This is often the most critical technical question for aerosol manufacturers.
3.1 Pressure Filling vs. Cold Filling
There are two main process routes for propellant filling in pharmaceutical aerosols:
Pressure filling is the industry standard. The process sequence is: liquid formulation filling → valve crimping → propellant injection under pressure. A booster pump draws propellant from the storage vessel, pressurizes it to liquid state, and delivers it to the metering cylinder for filling. Pressure filling works well for most HFA propellants and compressed gases, with mature equipment technology and high production efficiency.
Cold filling requires cooling the propellant to 5°C below its boiling point before filling. This process demands cooling the containers and materials to approximately 20°C, resulting in higher capital investment and energy consumption. Cold filling is typically reserved for heat sensitive formulations or specialized production requirements.
3.2Tube Valve vs BOV (Bag on Valve) Systems
From a packaging structure perspective, pharmaceutical aerosols fall into two main categories:
Tube Valve systems house both the drug formulation and the propellant together in the aerosol can without physical separation. This is the traditional aerosol architecture. The process flow is: container feeding → liquid filling → valve insertion → crimping → propellant filling → quality inspection and packaging.
BOV (bag onvalve) systems achieve complete physical separation between drug and propellant — the drug is contained in a flexible bag inside the can, while the propellant occupies the space between the bag and the can wall. This design offers superior safety and hygiene, as the drug never contacts the propellant, making it ideal for high purity or stability sensitive medications. The process flow is: container feeding → valve insertion → propellant filling and crimping → forced liquid filling. For new entrants to aerosol manufacturing, bag on valve equipment is widely recommended due to its simplicity, safety, reliability, and moderate cost.
3.3 Key Equipment Specifications
When selecting filling equipment, manufacturers should focus on the following parameters:
Filling accuracy: Modern fully automatic aerosol filling lines achieve accuracy of ±0.5% to ±1%, enabled by servo control technology
Production throughput: Typical aerosol filling lines operate at 1,200–1,500 cans per hour
Versatility: Equipment should accommodate multiple can sizes (diameter 35–75 mm) and different propellant types
Safety features: HFA and hydrocarbon propellant filling requires explosion proof design and leak detection systems
4. Six Key Considerations for Propellant Selection
Selecting the right propellant involves balancing multiple factors. Here are the six dimensions that technical decision-makers should evaluate:
4.1 Drug Compatibility
Drug‑propellant compatibility is the primary consideration. The propellant must not react chemically with the active pharmaceutical ingredient (API) or degrade the drug. HFA propellants excel in this regard — they are chemically stable and compatible with most APIs.
4.2 Target Atomization Performance
Different clinical applications require different droplet sizes. Pulmonary inhalation products require fine droplets (typically mass median aerodynamic diameter of 1–5 μm) for deep lung deposition. HFA propellants are the preferred choice for inhalation aerosols due to their superior atomization characteristics. Topical aerosols are less demanding in terms of droplet fineness, making compressed gases or hydrocarbons viable options.
4.3 Safety Profile
Safety encompasses multiple dimensions: inhalation toxicity, skin irritation, systemic toxicity, and flammability/explosion risk. HFA propellants have an excellent safety profile — they are non‑toxic and minimally irritating. Hydrocarbons pose flammability risks, requiring explosion‑proof filling equipment and strict storage protocols.
4.4 Environmental Compliance
CFCs have been completely phased out — this is an irreversible regulatory trend. While HFAs are ozone‑friendly, they still have measurable global warming potential (GWP). Next‑generation low‑GWP propellants such as HFO‑1234ze are under investigation and may emerge as future alternatives. Manufacturers should monitor regulatory trends regarding GWP.
4.5 Economics
HFA propellants are significantly more expensive than compressed gases and hydrocarbons. For applications where performance permits, compressed gases offer the lowest‑cost solution. However, for premium products such as inhalation aerosols, the performance advantages of HFA propellants justify their price premium.
4.6 Process Compatibility
Different propellant types impose different requirements on filling equipment. HFA propellants need pressure‑rated filling systems and precise metering control. Hydrocarbons require explosion‑proof design and inert gas purging. Bag‑on‑valve systems need dedicated bag filling equipment.
5. Regulatory Landscape
5.1 International Framework
The Montreal Protocol on Substances that Deplete the Ozone Layer is the foundational treaty for phasing out CFCs globally, with over 160 signatory countries. The United States banned CFCs in non‑medical aerosols as early as 1978, with pMDIs exempted until suitable alternatives were developed.
5.2 Chinese Regulations
China acceded to the Montreal Protocol in 1991 and subsequently implemented a phased CFC elimination schedule for pharmaceutical aerosols. A 2006 directive required the cessation of CFC use in topical aerosols effective July 1, 2007, and in inhalation aerosols effective January 1, 2010. A further announcement in 2013 prohibited the use of CFCs in non‑inhalation pharmaceutical aerosols effective July 1, 2013.
5.3 Quality Standards
USP General Chapters <5> and <601> specify detailed requirements for product quality testing and performance characterization of inhalation and nasal aerosols, including delivered dose uniformity and aerodynamic particle size distribution. The FDA continues to update guidance on propellant transitions, emphasizing in vitro comparability and non‑clinical safety assessments. Manufacturers developing new products should reference these standards to ensure compliance.
6. Future Trends in Propellant Technology
6.1 Low-GWP Propellants
As climate change concerns intensify, the GWP of HFA propellants is coming under increasing regulatory scrutiny. Next‑generation low‑GWP propellants such as HFO‑1234ze are under investigation, with physicochemical properties similar to HFAs, positioning them as potential next‑generation alternatives. The pharmaceutical aerosol industry is actively evaluating the feasibility and safety of these new propellants.
6.2 Evolving Regulatory Frameworks for Propellant Transitions
The FDA is actively considering updated data requirements for propellant transitions, aiming to promote global harmonization and accelerate the shift from high‑GWP to low‑GWP propellants. Manufacturers should plan ahead and build technical reserves to prepare for potential new waves of propellant substitution.
6.3 Traditional Chinese Medicine Topical Aerosols
Propellant substitution for traditional Chinese medicine (TCM) topical aerosols is also progressing, with HFA‑134a, HFA‑227ea, and dimethyl ether all being studied as viable CFC replacements. This area still offers considerable room for formulation development and process optimization.
7. Procurement Guide for Aerosol Manufacturers
7.1 New Product Development Pathway
For companies planning to enter aerosol manufacturing, we recommend the following step‑by‑step approach:
l Define product positioning: Inhalation or topical? Inhalation products require HFA propellants; topical products may be suitable for compressed gases or hydrocarbons.
l Assess filling process: Based on product characteristics and production scale, select one‑component or two‑component (bag‑on‑valve) system, and pressure filling or cold filling route.
l Equipment selection: Once the propellant type is confirmed, choose compatible filling equipment. New entrants are advised to start with bag‑on‑valve equipment; larger manufacturers should consider fully automatic filling lines.
l Pre‑regulatory assessment: Confirm that the chosen propellant meets registration requirements in target markets, and prepare CMC and stability data in advance.
7.2 Equipment Supplier Selection Criteria
As a filling equipment manufacturer, we advise production companies to evaluate potential suppliers on the following criteria:
l Process expertise: Does the supplier have proven experience in designing and manufacturing equipment compatible with your chosen propellant type?
l Accuracy assurance: Does the equipment achieve filling accuracy of ±1% or better?
l Safety features: Are explosion‑proof design and leak detection systems incorporated for HFA and hydrocarbon propellants?
l Full‑line capability: Can the supplier provide a complete production line solution covering container feeding, filling, crimping, water bath leak testing, and labeling?
l After‑sales support and customization: Does the supplier support equipment customization, facility layout planning, and engineering implementation?
8. Conclusion
Propellant selection for pharmaceutical aerosols is a systems engineering challenge spanning drug science, filling technology, regulatory compliance, and environmental responsibility. The transition from CFCs to HFAs reflects both growing global environmental awareness and continuous progress in aerosol filling technology.
For aerosol manufacturers, understanding the characteristics of different propellant types, mastering compatible filling processes, and staying current with regulatory trends and technological advances are the keys to successful product development and efficient production. As a specialized filling equipment manufacturer, we are committed to providing reliable equipment and process engineering support to aerosol producers worldwide — whether for high‑precision HFA inhalation aerosol filling or safe bag‑on‑valve propellant charging, we offer proven solutions.
If you are planning an aerosol production line or considering equipment upgrades, please contact us for professional technical support.
